Who Exports Olaparib from India — 70 Suppliers Behind a $922.2K Market
India's olaparib export market is supplied by 70 active exporters who collectively shipped $922.2K across 307 shipments. BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED leads with a 31.0% market share, followed by SANDOZ PRIVATE LIMITED and VAMA HEALTH WORLD LLP. The top 5 suppliers together control 72.9% of total export value, reflecting a concentrated market structure.
Top Olaparib Exporters from India — Ranked by Export Value
BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED is the leading olaparib exporter from India, holding a 31.0% share of the $922.2K market across 307 shipments from 70 exporters. The top 5 suppliers — BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED, SANDOZ PRIVATE LIMITED, VAMA HEALTH WORLD LLP, SPECIALITY MEDICINES LIMITED, SP ACCURE LABS PRIVATE LIMITED — collectively control 72.9% of total export value, indicating a highly concentrated market. Individual shares are: BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED (31.0%), SANDOZ PRIVATE LIMITED (17.6%), VAMA HEALTH WORLD LLP (11.7%), SPECIALITY MEDICINES LIMITED (8.3%), SP ACCURE LABS PRIVATE LIMITED (4.4%).
Top Olaparib Exporters from India
Ranked by export value · 70 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED PHARMACEUTICAL MATERAIL - OLAPARIBTABLETS 150 MG (OHARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USEPHARMACEUTICAL MATERAIL - OLAPARIBTABLETS 100 MG (O | $285.6K | 2 | 31.0% |
| 2 | SANDOZ PRIVATE LIMITED OLAPARIB FCT 150MG B/N: 32377858 (120 TAOLAPARIB FCT 100MG B/N: 32380402 (120 TAOLAPARIB FCT 150MG B/N: 32378842 (120 TA | $161.9K | 2 | 17.6% |
| 3 | VAMA HEALTH WORLD LLP HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USEHARMLESS MEDICINE FOR HUMAN CONSUMPTIONTABS. OLAPARIB 150MGOLAPARIB 150 MG NATCO BRAND BRACNAT | $107.6K | 2 | 11.7% |
| 4 | SPECIALITY MEDICINES LIMITED HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE | $76.4K | 2 | 8.3% |
| 5 | SP ACCURE LABS PRIVATE LIMITED HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USEOLAZYN 150 OLAPARIB TABLETS 150 MGOLAZYN 150 PHARMACEUTICAL FORMULATIONS | $40.4K | 1 | 4.4% |
| 6 | MATSUN EXPORTS HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE | $39.2K | 1 | 4.3% |
| 7 | KINGS GLOBAL BIOTECH LIMITED TABOLASP 150 OLAPARIB 150MG (PHARMACEUTICAL PRODUCTS.OLABIR 150 MG | $21.6K | 1 | 2.3% |
| 8 | SPR ONCOCARE PRIVATE LIMITED OLAPARIB 150 MG NATCO BRAND BRACNAT | $13.9K | 1 | 1.5% |
| 9 | GLOBYZ BIOPHARMA PRIVATE LIMITED HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE | $12.7K | 1 | 1.4% |
| 10 | GALAXY SUPER SPECIALITY | $10.6K | 2 | 1.2% |
| 11 | VEA IMPEX (I) PRIVATE LIMITED | $8.6K | 4 | 0.9% |
| 12 | HEET HEALTHCARE PRIVATE LIMITED TABOLASP 150 OLAPARIB 150MG (PHARMACEUTICAL PRODUCTS.OLABIR 150 MG | $8.3K | 4 | 0.9% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Olaparib exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| VAMA HEALTH WORLD LLP | Not Listed | Yes | No | Not verified | VAMA HEALTH WORLD LLP's manufacturing facilities possess various global certific |
| BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED | Not Listed | Yes | No | Not verified | BDR Pharmaceuticals International Private Limited is listed among WHO-GMP certif |
| SANDOZ PRIVATE LIMITED | Not Listed | Yes | No | Not verified | Sandoz Private Limited is listed among WHO-GMP certified manufacturers. |
| SPECIALITY MEDICINES LIMITED | Not Listed | Yes | No | Not verified | Speciality Medicines Limited is listed among WHO-GMP certified manufacturers. |
| SP ACCURE LABS PRIVATE LIMITED | Not Listed | Yes | No | Not verified | SP Accure Labs Private Limited is listed among WHO-GMP certified manufacturers. |
| MATSUN EXPORTS | Not Listed | Yes | No | Not verified | Matsun Exports is listed among WHO-GMP certified manufacturers. |
| KINGS GLOBAL BIOTECH LIMITED | Not Listed | Yes | No | Not verified | Kings Global Biotech Limited is listed among WHO-GMP certified manufacturers. |
| SPR ONCOCARE PRIVATE LIMITED | Not Listed | Yes | No | Not verified | SPR Oncocare Private Limited is listed among WHO-GMP certified manufacturers. |
| GLOBYZ BIOPHARMA PRIVATE LIMITED | Not Listed | Yes | No | Not verified | Globyz Biopharma Private Limited is listed among WHO-GMP certified manufacturers |
| GALAXY SUPER SPECIALITY | Not Listed | Yes | No | Not verified | Galaxy Super Speciality is listed among WHO-GMP certified manufacturers. |
TransData Nexus reviewed the regulatory standing of 10 leading Olaparib exporters from India. 0 hold US FDA facility approvals, 10 maintain WHO-GMP certification, and 0 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Olaparib sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is renowned for its production of active pharmaceutical ingredients (APIs). The city's pharmaceutical landscape is characterized by a robust infrastructure supporting large-scale API manufacturing, making it a pivotal hub for sourcing raw materials essential for drug formulation.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a prominent center for pharmaceutical formulations. Ahmedabad hosts major companies like Zydus Lifesciences Limited (formerly Cadila Healthcare Limited), which specializes in generic drugs and formulations. Vadodara complements this with its own pharmaceutical manufacturing capabilities, contributing significantly to the region's output. This cluster's focus on finished dosage forms makes it ideal for sourcing ready-to-market pharmaceutical products.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a critical export gateway for India's pharmaceutical industry. Mumbai, being a major port city, facilitates the international distribution of pharmaceutical products. The presence of numerous pharmaceutical companies in this region underscores its role in global supply chains, ensuring efficient export logistics for drugs like Olaparib.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi and Nalagarh in Himachal Pradesh have emerged as significant pharmaceutical hubs, largely due to favorable tax incentives. Baddi, in particular, is recognized as Asia's largest pharmaceutical hub, housing over 3,100 factories with an annual turnover of approximately ₹60,000 crore. This region's cost-effective manufacturing environment makes it attractive for pharmaceutical production.
5Sourcing Recommendations
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities of suppliers in the Ahmedabad-Vadodara region for formulations and Hyderabad for APIs to ensure they meet quality standards for Olaparib production.
- Leverage Export Infrastructure: Utilize the export facilities in the Mumbai-Thane-Raigad region to streamline international distribution channels for Olaparib.
- Consider Cost Advantages: Explore manufacturing options in the Baddi-Nalagarh region to benefit from tax incentives and cost-effective production processes.
- Ensure Regulatory Compliance: Verify that all potential suppliers comply with regulatory standards set by authorities such as the Central Drugs Standard Control Organisation (CDSCO) and the Directorate General of Foreign Trade (DGFT) to ensure product quality and legality.
By strategically engaging with these pharmaceutical clusters, TransData Nexus can optimize its supply chain for Olaparib, ensuring quality, cost-effectiveness, and efficient distribution.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Olaparib exporters from India
Purna Pharmaceuticals — Ampersand Capital acquires Purna Pharmaceuticals
Ampersand Capital Partners acquired Purna Pharmaceuticals, a Belgium-based provider of development and manufacturing services for liquid and semi-solid dosage forms in the pharmaceutical sector. IMPACT: This acquisition may enhance Purna Pharmaceuticals' capacity to support Olaparib production, potentially affecting export dynamics.
Impact: This acquisition may enhance Purna Pharmaceuticals' capacity to support Olaparib production, potentially affecting export dynamics.
Sandoz Private Limited — Sandoz reports strong H1 2025 results with accelerated sales growth
Sandoz reported strong half-year results for 2025, with accelerated sales growth in the second quarter, indicating robust operational performance. IMPACT: The strong performance may lead to increased production capacity, potentially influencing Olaparib export volumes.
Impact: The strong performance may lead to increased production capacity, potentially influencing Olaparib export volumes.
Sandoz Private Limited — Novartis announces USD 15 billion share buyback and Sandoz spin-off
Novartis announced a USD 15 billion share buyback and the Board's endorsement of a Sandoz spin-off, aiming to create a standalone company. IMPACT: The spin-off could lead to strategic realignments affecting Sandoz's focus on Olaparib exports.
Impact: The spin-off could lead to strategic realignments affecting Sandoz's focus on Olaparib exports.
Common Questions — Olaparib Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which olaparib supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED leads with 15 recorded shipments worth $285.6K. SANDOZ PRIVATE LIMITED (57 shipments) and VAMA HEALTH WORLD LLP (20 shipments) are also established high-volume exporters.
Q How many olaparib manufacturers are there in India?
India has 70 active olaparib exporters with a combined export market of $922.2K across 307 shipments to 49 countries. The top 5 suppliers hold 72.9% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for olaparib from India?
Average FOB unit price: $683.96 per unit, ranging from $0.01 to $9249.59. Average shipment value: $3.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 70 verified Indian exporters of Olaparib ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 307 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 49 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
307 Verified Shipments
70 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists